RU2257895C2 - Применение (r)-ибупрофенметансульфонамида и его солей для лечения и предотвращения реакций отторжения трансплантируемых органов - Google Patents

Применение (r)-ибупрофенметансульфонамида и его солей для лечения и предотвращения реакций отторжения трансплантируемых органов Download PDF

Info

Publication number
RU2257895C2
RU2257895C2 RU2003126600/15A RU2003126600A RU2257895C2 RU 2257895 C2 RU2257895 C2 RU 2257895C2 RU 2003126600/15 A RU2003126600/15 A RU 2003126600/15A RU 2003126600 A RU2003126600 A RU 2003126600A RU 2257895 C2 RU2257895 C2 RU 2257895C2
Authority
RU
Russia
Prior art keywords
kidney
transplantation
ischemia
prophylaxis
treatment
Prior art date
Application number
RU2003126600/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2003126600A (ru
Inventor
Риккардо БЕРТИНИ (IT)
Риккардо БЕРТИНИ
Франческо КОЛОТТА (IT)
Франческо Колотта
Роберто НОВЕЛЛИНИ (IT)
Роберто НОВЕЛЛИНИ
Original Assignee
Домпе С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Домпе С.П.А. filed Critical Домпе С.П.А.
Publication of RU2003126600A publication Critical patent/RU2003126600A/ru
Application granted granted Critical
Publication of RU2257895C2 publication Critical patent/RU2257895C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
RU2003126600/15A 2001-02-02 2002-01-30 Применение (r)-ибупрофенметансульфонамида и его солей для лечения и предотвращения реакций отторжения трансплантируемых органов RU2257895C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2001A000206 2001-02-02
IT2001MI000206A ITMI20010206A1 (it) 2001-02-02 2001-02-02 Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz

Publications (2)

Publication Number Publication Date
RU2003126600A RU2003126600A (ru) 2005-02-27
RU2257895C2 true RU2257895C2 (ru) 2005-08-10

Family

ID=11446717

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003126600/15A RU2257895C2 (ru) 2001-02-02 2002-01-30 Применение (r)-ибупрофенметансульфонамида и его солей для лечения и предотвращения реакций отторжения трансплантируемых органов

Country Status (26)

Country Link
US (1) US7560487B2 (https=)
EP (1) EP1355641B1 (https=)
JP (1) JP2004517948A (https=)
KR (1) KR100857898B1 (https=)
CN (1) CN1561205A (https=)
AT (1) ATE304846T1 (https=)
AU (1) AU2002250869B2 (https=)
BR (2) BR0206804A (https=)
CA (1) CA2432432C (https=)
CZ (1) CZ303665B6 (https=)
DE (1) DE60206245T2 (https=)
DK (1) DK1355641T3 (https=)
EE (1) EE05233B1 (https=)
ES (1) ES2248541T3 (https=)
HU (1) HU229070B1 (https=)
IL (1) IL157180A (https=)
IT (1) ITMI20010206A1 (https=)
MX (1) MXPA03006686A (https=)
NO (1) NO334285B1 (https=)
NZ (1) NZ526655A (https=)
PL (1) PL215109B1 (https=)
PT (1) PT1355641E (https=)
RU (1) RU2257895C2 (https=)
SK (1) SK287632B6 (https=)
WO (1) WO2002062330A2 (https=)
ZA (1) ZA200304861B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2508099C2 (ru) * 2006-11-13 2014-02-27 Такеда Фармасьютикалз Норт Америка, Инк. Способы сохранения функции почек с использованием ингибиторов ксантин оксидоредуктазы

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1579859E (pt) * 2004-03-25 2007-03-30 Dompe Pha R Ma Spa Res & Mfg Utilização de n-(2-aril-propionil)-sulfonamidas pata o tratamento de lesões da medula espinal
EP1883405A4 (en) 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
CA2812034C (en) 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US20200003787A1 (en) * 2017-03-15 2020-01-02 Numares Ag Method for Using a Marker Set for Determining the Risk of Kidney Rejection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008901C1 (ru) * 1991-03-29 1994-03-15 Донецкий государственный медицинский институт им.М.Горького Способ фармакологической защиты децентрализованной почки
RU2126262C1 (ru) * 1992-09-17 1999-02-20 Амген Боулдер Инк. Фармацевтическая композиция
RU2140918C1 (ru) * 1993-06-16 1999-11-10 Смитклайн Бичам Корпорейшн Три-замещенные имидазолы, обладающие терапевтическими свойствами, способ получения, фармацевтическая композиция, способ лечения
WO2000024710A1 (en) * 1998-10-23 2000-05-04 Dompe' S.P.A. N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879283A (en) * 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
JPH08231413A (ja) * 1994-12-29 1996-09-10 Mochida Pharmaceut Co Ltd 臓器障害に基づく疾患の予防・治療剤
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008901C1 (ru) * 1991-03-29 1994-03-15 Донецкий государственный медицинский институт им.М.Горького Способ фармакологической защиты децентрализованной почки
RU2126262C1 (ru) * 1992-09-17 1999-02-20 Амген Боулдер Инк. Фармацевтическая композиция
RU2140918C1 (ru) * 1993-06-16 1999-11-10 Смитклайн Бичам Корпорейшн Три-замещенные имидазолы, обладающие терапевтическими свойствами, способ получения, фармацевтическая композиция, способ лечения
WO2000024710A1 (en) * 1998-10-23 2000-05-04 Dompe' S.P.A. N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI L. et al. The relationship between cytokines in MLC supernatants and acute rejection after renal transplantation. Transplant Proc. 2000, Nov; 32(7):2531-4. KUTUKCLER N. et al. The value of posttransplant monitoring of interleukin (IL)-2, IL-3, IL-4, IL-6, IL-8, and soluble CD23 in the plasma of renal allograft recipients. Transplantation. 1995 Feb 15;59(3):333-40. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2508099C2 (ru) * 2006-11-13 2014-02-27 Такеда Фармасьютикалз Норт Америка, Инк. Способы сохранения функции почек с использованием ингибиторов ксантин оксидоредуктазы

Also Published As

Publication number Publication date
EE200300340A (et) 2003-10-15
WO2002062330A2 (en) 2002-08-15
CA2432432A1 (en) 2002-08-15
DE60206245D1 (de) 2006-02-02
NO20033273D0 (no) 2003-07-18
DK1355641T3 (da) 2005-10-17
NO20033273L (no) 2003-07-18
KR20030074725A (ko) 2003-09-19
BRPI0206804B1 (pt) 2018-09-25
US7560487B2 (en) 2009-07-14
KR100857898B1 (ko) 2008-09-10
ZA200304861B (en) 2004-06-30
CZ303665B6 (cs) 2013-02-20
MXPA03006686A (es) 2004-05-31
WO2002062330A3 (en) 2003-04-03
PT1355641E (pt) 2005-11-30
ES2248541T3 (es) 2006-03-16
AU2002250869B2 (en) 2006-10-19
ITMI20010206A1 (it) 2002-08-02
NZ526655A (en) 2005-02-25
HUP0303024A2 (hu) 2003-12-29
NO334285B1 (no) 2014-01-27
ATE304846T1 (de) 2005-10-15
EP1355641B1 (en) 2005-09-21
CA2432432C (en) 2008-03-25
DE60206245T2 (de) 2006-06-14
HUP0303024A3 (en) 2005-07-28
SK287632B6 (sk) 2011-04-05
PL215109B1 (pl) 2013-10-31
JP2004517948A (ja) 2004-06-17
EE05233B1 (et) 2009-12-15
PL363576A1 (en) 2004-11-29
CN1561205A (zh) 2005-01-05
RU2003126600A (ru) 2005-02-27
SK9732003A3 (en) 2003-11-04
BR0206804A (pt) 2004-02-03
EP1355641A2 (en) 2003-10-29
HU229070B1 (hu) 2013-07-29
IL157180A (en) 2009-06-15
CZ20032095A3 (en) 2004-05-12
US20040102520A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
Andoh et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506
Sandberg et al. Treatment with an interleukin-1 receptor antagonist protein prolongs mouse islet allograft survival
US12060440B2 (en) Cyclophilin inhibitors and uses thereof
RU2257895C2 (ru) Применение (r)-ибупрофенметансульфонамида и его солей для лечения и предотвращения реакций отторжения трансплантируемых органов
Chang et al. Ex-vivo generation of drug-eluting islets improves transplant outcomes by inhibiting TLR4-Mediated NFkB upregulation
AU2002250869A1 (en) Use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
US4180588A (en) Immunosuppressant
HU224958B1 (en) Use of teophyllin derivatives for the preparation of pharmaceutical compositions for the prevention and treatment of shock
TWI917366B (zh) 親環蛋白抑制劑及其用途
Poisson Synthesis and In Vitro Applications of Ice Recrystallization Inhibitors
JOHNSSON et al. Recovery of hyaluronan during perfusion of small bowel transplantation reflects rejection
Briard The Rational Design and Use of Novel Small-Molecule Ice Recrystallization Inhibitors for the Cryopreservation of Hematopoietic Stem Cells and Red Blood Cells
CA2185661C (en) Novel iron chelator and inhibitor of iron-mediated oxidation
Sanadi et al. In vivo Acetylation of Natural Amino Acids
WO1993003733A1 (en) Syntheses, pharmaceutical composition and method of application of (2'-5') oligoadenylate analogues
HK1071853A (en) Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
NZ746140A (en) Ambrisentan for use in the treatment of acute renal failure

Legal Events

Date Code Title Description
PC4A Invention patent assignment

Effective date: 20060811

PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20150916

PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20151027

MM4A The patent is invalid due to non-payment of fees

Effective date: 20200131